Two-Year US Pharmacovigilance Report on Brodalumab

INTRODUCTION: Brodalumab is a human interleukin-17 receptor A antagonist indicated for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies. In the U...

Descripción completa

Detalles Bibliográficos
Autores principales: Lebwohl, Mark, Leonardi, Craig, Wu, Jashin J., Armstrong, April, Rawnsley, Nicole, Merchant, Mohammed, Alexander, Binu, Jacobson, Abby
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7859129/
https://www.ncbi.nlm.nih.gov/pubmed/33337520
http://dx.doi.org/10.1007/s13555-020-00472-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7859129/
https://www.ncbi.nlm.nih.gov/pubmed/33337520
http://dx.doi.org/10.1007/s13555-020-00472-x

Ejemplares similares